Intelligence
Know what's happening in FDA enforcement before it happens to you. Warning letter analysis, 483 trends, and enforcement pattern recognition — written for quality teams, not lawyers.
What happens here
FDA Warning Letter Analysis
Every significant warning letter broken down — what FDA cited, why it matters, and what it means for your quality system.
483 Trend Reports
Pattern analysis across 483 observations. See which findings are escalating and where your risk exposure sits.
Regulatory Guidance Updates
ICH, EMA, USP, and FDA guidance changes — summarized with plain-language impact assessment for your operations.
Weekly Intelligence Digests
Curated weekly roundup of the enforcement actions and guidance changes that matter most to small pharma quality teams.
From DSRV
Subscribe free to unlock full articles and weekly round-ups.
April 2026
Usable Procedures Are Not Defensible Quality Decisions
Modern AI tools can make SOPs clearer and easier to follow. But inspectors do not cite companies for unclear formatting. They cite them for weak investigations, missing escalation logic, and decisions that cannot be traced to evidence. Usability and defensibility are different problems.
DSRV Intelligence
·9 min read
March 2026
ICH Q14 Analytical Procedure Development: What QA Teams Need to Know
ICH Q14 introduces a structured, science-based approach to analytical procedure development. We break down the key concepts, lifecycle management requirements, and how they align with existing Q2 and Q12 guidelines.
DSRV Intelligence
·8 min read
February 2026
Risk-Based Cleaning Validation: Applying ICH Q9 Principles in Practice
Cleaning validation remains one of the most inspection-cited areas in pharmaceutical manufacturing. This article explores how a risk-based framework under ICH Q9 Rev.1 can rationalise your validation strategy.
DSRV Intelligence
·11 min read
January 2026
FDA's Evolving Stance on Real-Time Release Testing (RTRT)
The FDA has issued new draft guidance on RTRT as part of its modernisation initiative. We examine the regulatory pathway, technical requirements, and what this means for PAT-enabled manufacturing lines.
DSRV Intelligence
·9 min readFull articles unlock with a free subscription.
No spam. Unsubscribe any time. Weekly regulatory round-up included.
Found something in the intelligence that affects your site?
See how Response Strategy can help
The regulatory world doesn't slow down.
Neither should you.
Join QA professionals, regulatory affairs specialists, and stability scientists who rely on DSRV for weekly regulatory updates, quality science deep-dives, and expert commentary.
Free forever. No spam. Unsubscribe any time.
Will your documents hold up under inspection?
Submit your SOP, deviation report, CAPA, or investigation. Get a scored risk diagnostic across six enforcement-informed dimensions — with specific findings, inspection-risk signals, and recommended fixes.